►Table S1 summarizes time and location characteristics of arterial occlusive events associated with BCR-ABL tyrosine kinase inhibitor (TKIs). A link exists between location of the obstructed artery and the clinical presentation. With dasatinib, nilotinib, and ponatinib, arterial occlusive events occurred preferentially in the cardiovascular circulation leading to myocardial infarction and angina pectoris.
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However, numerous patients also developed ischemic events in both the peripheral and cerebral circulation. To our knowledge, the etiology of these events is unknown. Peripheral and cerebral occlusive events might be the result of embolism or might be the consequence of on-site atherosclerotic lesion rupture/erosion. 8 The differentiation between the two is difficult to establish because both of them shared similar clinical pictures. It has to be noted that arterial emboli can arise both from aortic atherosclerotic lesions and from atrial fibrillation. Nilotinib and ponatinib have been both associated with common occurrence of atrial fibrillation, whereas these events occurred rarely with imatinib.
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Nevertheless, no causal relationship has been established and the incidence of drug-induced atrial fibrillation is too low to be responsible for the majority of arterial occlusive events with these two treatments. Remarkably, numerous patients taking nilotinib developed peripheral arterial occlusive disease (PAOD) with preferential tropism for lower limbs and small vessel, indicating a pathology close to those found in diabetic patients, and potentially linking nilotinibinduced diabetes to the development of peripheral occlusive events. 12, 13 This indicate that PAOD occurring with nilotinib might be the result of atheroemboli that come from atherosclerotic lesions and are formed by small cholesterol crystal particles, rather than arterial emboli.
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However, even if the three new-generation TKIs are close regarding the location of arterial thrombosis, there are discrepancies regarding the delay between the initiation of therapy and the development of cardiovascular events (►Table S1). For ponatinib, arterial occlusive events developed quickly and are more frequent during the first and the second years of treatment (14.5 and 14.1% respectively) than after (10.5% during the third year and 7.2% after 3 years).
14 However, it appears unclear if this reduction over time is real or is an artifact due to ponatinib dose reduction (i.e., recommendations were provided by authorities to decrease ponatinib doses in clinical trials to minimize the risk of blood clot). 15 Nilotinib-associated cardiovascular events developed less quickly and the rate of these events is constant over time with gradual increase of cardiovascular events and no plateau obtain after 100 months of treatment.
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It takes longer in young patients and in patients without prior risk factors to develop an arterial thrombotic events with nilotinib, 16 fostering the hypothesis of progressive development of stenosis or progression of preexisting atherosclerotic lesions. For imatinib, dasatinib, and bosutinib, few data are available. One report described short time-to-event with dasatinib, 17 whereas the rare arterial occlusive events in patients treated with imatinib occur very lately.
►Table S1 also reports risk factors linked to the risk of arterial thromboembolism with new-generation BCR-ABL TKIs. Cardiovascular risk factors are difficult to highlight due to the small size of the population in clinical trials and the selection bias (e.g., older patients are usually excluded from clinical trials). However, several analyses demonstrated that arterial occlusive events occurred preferentially in nilotinibtreated patients with preexisting atherosclerotic risk factor(s) (i.e., arterial hypertension, overweight, smoking, hypercholesterolemia, diabetes mellitus) rather than in patients with no comorbidities, but that neither antiplatelet drugs nor lipidlowering treatments seem to prevent the occurrence of these events. 6, 7, 16, 18 Similarly, atherothrombotic events in ponatinib-treated patients also occurred preferentially in patients with cardiovascular risk factors. In correlation with the occurrence of arterial thrombotic events mostly in high-risk patients, case reports raised the concern that PAOD occurred preferentially on pathological arteries. Indeed, several case reports described nilotinib-associated PAOD resistant to surgical and medical treatment (i.e., stent implantation, aspirin), suggesting a negative impact of nilotinib on preexisting atherosclerotic lesions, and possibly on vascular endothelium compliance. [19] [20] [21] [22] Symptoms of PAOD usually improve when nilotinib is discontinued, without surgery. 23 An autopsy of a nilotinib-treated patient subsequently to myocardial infarction also revealed obliterating artery disease (i.e., obliterating coronary sclerosis and atherosclerosis of the infrarenal aorta)
. 18 Yet, it is important to note that with both nilotinib and ponatinib, arterial thromboembolism also occurred in young patients, without prior risk factor or without atherosclerotic lesion prior toTKI initiation. 6, 16, 22, 23 For dasatinib and bosutinib, too low arterial occlusive events were reported to correlate risk factors and arterial occlusive events. 14 For the future, it will be interesting to obtain more data on these cardiovascular events that may occur during dasatinib and bosutinib treatments to identify patients at risk and develop predictive scores similarly than those existing with nilotinib.
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Method
Literature search was performed on PubMed on April 4, 2016, and updated on July 11, 2017. Articles published in languages other than English were excluded from the analysis. Primary criteria were pathophysiological explanation of arterial thrombotic events. Abstracts and full-text articles were reviewed with a focus on atherogenesis, plaque rupture, platelet functions, and their link with the development of arterial thrombosis with BCR-ABL TKIs. The reference section of identified articles was also examined.
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• Platelet. ((((((((((((((vascular A key event in the pathophysiology of atherosclerosis is the dysfunction of the endothelium, which results in endothelium permeability, enabling migration and trapping of lipoprotein into the intima. Modified lipoproteins in the intima activate endothelial cells and promotes the expression of cell adhesion molecules on the vessel wall, endorsing leukocyte migration into the intima. 31 Among adhesion molecules involved in atherosclerosis development, E-selectin, P-selectin, VCAM-1, and ICAM-1 possess major functions in leukocyte recruitment. 32 E-selectin and P-selectin are involved in the capture and rolling of monocytes, whereas ICAM-1 and VCAM-1 are implicated in leukocyte firm adhesion. 31 Monocyte transmigration is finally mediated by VCAM-1 and various chemokines produced by ECs, macrophages, and vascular smooth muscle cells.
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Additionally to the role of the endothelium in early atherosclerosis development, a recent in vivo study reports that vascular leakage is a marker to distinguish stable from rupture-prone atherosclerotic plaques (i.e., plaques are more prone to rupture subsequently to increase leukocytes migrating to the intima).
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Chronic inflammation is a key feature of atherosclerotic diseases and is involved in all stages of the disease, from atheroma formation to plaque rupture. 34 Inflammation is initiated by retention and oxidative modification of lipids and lipoproteins in the vessel wall that results in monocyte chemotaxis and recruitment of blood immune cells (particularly monocytes and T lymphocytes; ►Fig. S1). 34 Thereafter, immune cells initiate inflammatory reactions, with transformation of monocytes to macrophages and activation of T lymphocytes, predominantly to proinflammatory lymphocytes (i.e., Th1 subtype). 35 Macrophages within the atheroma uptake oxidized lipoprotein by scavenger receptor (e.g., SR-A and CD36) and transform to foam cells. 34 Macrophages also express and secrete matrix metalloproteinases (MMPs) that degrade extracellular matrix, thin the fibrous cap, and subsequently destabilize the atherosclerotic plaque. 36 Macrophages, foam cells, and activated T-cells release high content of proinflammatory mediators (e.g., IL-6, IL-12, and TNF-α), accentuating inflammation within the intima. Finally, mast cells represent only a small proportion of cells in atherosclerosis but are important players in plaque growth and destabilization. 37 During atherosclerosis, they are recruited within the intima and may degranulate, inducing release of high content of TNF-α, tryptase and chymase, two enzymes able to activate MMP proform. 38 Episodes of acute inflammation are notably associated with rapid atherosclerosis development and play a role in plaque rupture or fissuring, increasing the inflammatory process within the plaque.
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Atherosclerosis is considered as a fibroproliferative disease. Indeed, during atherogenesis, vascular smooth muscle cells (VSMCs) undergo phenotypic switch from a contractile phenotype to a migratory and secretion phenotype. They acquire the capacity to migrate and produce extracellular matrix (ECM) proteins, additionally to a greater capacity to proliferate. 40 The stability of atherosclerotic plaque correlates to the thickness of its fibrous cap, which is composed of SMC in a collagenous-proteoglycan matrix. Different mechanisms may contribute to fibrous cap thickening, notably a high MMP concentration (►Fig. S2) or high SMC mortality that directly reduces ECM content in the fibrous cap. Therefore, the content of VSMCs within the plaque and their capacity to secrete ECM components directly correlate with the thickness of the fibrous cap and therefore play a major role to differentiate rupture-prone plaque from stable plaque. 40 Additionally, VSMCs are involved in plaque repair in case of rupture through their capacity to proliferate and synthesize ECM. Thus, the presence of VSMCs in advanced lesions is beneficial and the TH Open destabilization of atherosclerotic plaques might be due to alteration of the balance between VSMC proliferation and migration versus VSMC death and senescence that might promote atherogenesis and plaque instability. 
